European Society for Medical Oncology Congress

The latest news from ESMO, including researcher interviews and physician perspective.


Meeting News

ESMO presents awards to four clinicians

October 1, 2019
BARCELONA, Spain — The European Society for Medical Oncology presented awards to four clinicians and scientists during its annual congress…
Meeting NewsPerspective

Targeted therapy shows benefit in advanced cholangiocarcinoma

October 1, 2019
BARCELONA, Spain — Ivosidenib improved outcomes among patients with isocitrate dehydrogenase-mutated advanced cholangiocarcinoma, according to…
Meeting NewsPerspective

Nivolumab extends OS in advanced esophageal squamous cell carcinoma

October 1, 2019
BARCELONA, Spain — Nivolumab extended survival compared with chemotherapy among patients with advanced or recurrent esophageal squamous cell…
Meeting NewsPerspective

Atezolizumab extends PFS in metastatic urothelial cancer

September 30, 2019
BARCELONA, Spain — The addition of atezolizumab to chemotherapy prolonged PFS for patients with metastatic urothelial cancer, according to…
Meeting NewsPerspective

Addition of veliparib to platinum chemotherapy extends PFS in BRCA-mutated breast cancer

September 30, 2019
The addition of veliparib to carboplatin and paclitaxel significantly improved PFS for patients with metastatic breast cancer who have germline…

Nivolumab-ipilimumab combination benefits women with advanced cervical cancer

September 30, 2019
BARCELONA, Spain — Nivolumab in combination with ipilimumab conferred clinical benefit for women with recurrent or metastatic cervical cancer…
Meeting News

Cabazitaxel improves outcomes among certain men with metastatic prostate cancer

September 30, 2019
BARCELONA, Spain — Cabazitaxel significantly improved outcomes compared with androgen receptor-targeted therapies for certain men with…
Meeting NewsPerspective

Triplet therapy improves outcomes in BRAF V600E-mutant metastatic colorectal cancer

September 30, 2019
BARCELONA, Spain — Triplet therapy with encorafenib, cetuximab and binimetinib significantly extended OS compared with standard treatment for…
Meeting NewsPerspective

Olaparib trial reveals ‘first personalized treatment strategy for prostate cancer’

September 30, 2019
BARCELONA, Spain — Olaparib significantly improved radiographic PFS compared with horomone therapy for men with metastatic castration-resistant…

Rivoceranib fails to significantly improve OS in advanced gastric cancer

September 29, 2019
BARCELONA, Spain — Rivoceranib failed to significantly improve OS in an overall study population with advanced gastric cancers, according to…